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Background: Difficulty sleeping is common among patients with fibromyalgia (FM); however, its impact on
health-related quality of life (HRQoL) is not well understood. The aim of the current study was to assess the burden
of sleep difficulty symptoms on HRQoL among patients with FM.
Methods: The current study included data from the 2009 National Health and Wellness Survey (N=75,000), which is
a cross-sectional, Internet-based survey representative of the adult US population. The prevalence of sleep difficulty
symptoms among patients with FM (n=2,196) were compared with matched controls (n=2,194), identified using
propensity-score matching. Additionally, the relationship between the number of sleep difficulty symptoms (none,
one, or two or more) and HRQoL (using the SF-12v2) was assessed using regression modeling, controlling for
demographic and health history variables.
Results: Of the 2,196 patients with FM, 11.2% reported no sleep difficulty symptoms, 25.7% reported one sleep
difficulty symptom, and 63.05% reported two or more sleep difficulty symptoms. The prevalence of sleep difficulty
symptoms was significantly higher than matched controls. Patients with one and two sleep difficulty symptoms
both reported significantly worse HRQoL summary and domain scores relative to those with no sleep difficulty
symptoms (all p<.05). Further, the relationship between sleep difficulty symptoms and HRQoL was significantly
different between those with FM than matched controls, suggesting a uniqueness of the burden of sleep
difficulties within the FM population.
Conclusions: Among the FM population, sleep difficulty symptoms were independently associated with
clinically-meaningful decrements in mental and physical HRQoL. These results suggest that greater emphasis in the
treatment of sleep difficulty symptoms among the FM population may be warranted.
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Fibromyalgia (FM) is a chronic disorder characterized by
widespread pain of the muscle and connective tissues,
and pain in response to touch or pressure [1]. Often ac-
companied by non-specific symptoms, such as fatigue,
depressive mood, and sleep difficulties [2], FM affects
approximately 5 million Americans [3]. As it largely
affects a working-age population, and is associated with
increased resource use and disability, FM is responsible* Correspondence: marco.dibonaventura@kantarhealth.com
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reproduction in any medium, provided the orfor substantial societal costs. Indeed, prior research on
managed care patients with FM found an average of
$10,911 (standard deviation = $16,860) in healthcare
expenses per patient per year during 2001–2004 [4].
Moreover, patients with FM reported short-term disabil-
ity at a greater rate than patients with rheumatoid arth-
ritis (20% vs. 15% reported any short-term leave) [4].
Costs also increase with severity, with patients with se-
vere symptoms reporting more than three times the
costs of patients with mild symptoms [5].
The societal impact of FM is not limited to economic
costs, however. Patients report that FM symptoms sub-
stantially impact their quality of life by disruptingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Wagner et al. BMC Musculoskeletal Disorders 2012, 13:199 Page 2 of 10
http://www.biomedcentral.com/1471-2474/13/199relationships, causing social isolation, reducing product-
ivity in activities of daily living, and complicating phys-
ical activity [6]. In a recent review of 37 studies,
Hoffman & Dukes found patients with FM report mental
health-related quality of life (HRQoL) scores 1 standard
deviation below the United States (US) population mean
and physical HRQoL scores 2 standard deviations below
the US population mean [7]. In fact, HRQoL among
patients with FM have been found to be similar to or
worse than patients with rheumatoid arthritis [8] and
other pain conditions [7].
Patients with FM have been found to be significantly
more likely to experience difficulties initiating or main-
taining sleep than controls (OR=4.56, 95% CI: 4.10-5.06)
[9]. In particular, previous studies have identified diffi-
culty falling asleep, staying asleep and waking up too
early in the morning as the most common sleep-related
symptoms among the FM population [9-12]. Such sleep
difficulties have been associated with negative affect and
mood, and pain, which, in turn, have been associated
with decrements in physical functioning [13-16]. More-
over, in qualitative interviews, patients with FM have
reported that sleep disturbances substantially affect their
quality of life [5,17]. However, few studies have assessed
the direct association of sleep difficulties with decre-
ments in HRQoL among this patient population.
There were several aims of the current study. One aim
was to determine the prevalence of sleep difficulty symp-
toms among those with FM in comparison with those
without FM. The second aim was to examine which
demographic and health history variables were signifi-
cantly associated with the presence of these sleep diffi-
culty symptoms. Lastly, the third aim was to examine
the relationship between these sleep difficulty symptoms
and HRQoL among patients with FM and determine




Data were obtained from the 2009 wave (N = 75,000) of
the US National Health and Wellness Survey. The
NHWS is an annual, cross-sectional, Internet-based sur-
vey administered to a sample of adults (18 years andTable 1 Criteria for establishing the presence of sleep difficul
No sleep difficulty symptoms One sleep difficulty s
Reporting none of the following: Reporting one of the f
• Difficulty falling asleep • Difficulty falling asl
• Difficulty staying asleep • Difficulty staying a
• Waking too early • Waking too early
• Insomnia
• Sleep difficulties (any)older) identified through a web-based panel. Members of
the panel are recruited through emails, Internet newslet-
ter campaigns, website banner placements, and registra-
tion with panel partners. All panel members agreed to
become panel members and registered through unique
email addresses. Of 501,239 persons contacted to partici-
pate in the 2009 NHWS, 92,759 responded (an 18.5% re-
sponse rate). Of those who responded, 75,000 gave their
informed consent, met the inclusion criteria (aged 18 or
over), and completed the survey instrument. To mimic
the demographic composition of the US general popula-
tion, a stratified random sampling procedure was imple-
mented when recruiting participants for the NHWS.
The NHWS sample, US census, and other national sur-
veys have been compared elsewhere [18]. Institutional
review board approval for the 2009 US NHWS was
granted by Essex IRB (Lebanon, NJ).
Sample




Although no sleep scale was included in the NHWS, all
respondents were asked whether they experienced diffi-
culty falling asleep, difficulty staying asleep, or waking
up too early (the response options for each item were ei-
ther yes or no). These items, which have been shown to
be the most common characteristics of sleep difficulties
among patients with FM [9-12], were used to operation-
ally define the presence of sleep difficulties. Severity of
sleep difficulties was established based on the number of
sleep difficulty symptoms reported (see Table 1). Similar
operationalizations have been used elsewhere [9,19]. The
primary independent variable was a three-level mutually
exclusive group variable: no sleep difficulty symptoms,
one sleep difficulty symptom, and two or more sleep dif-
ficulty symptoms.
FM
All respondents in the NHWS were presented with a list
of medical conditions and asked to select which ones
they had ever experienced (“which of the followingties in patients
ymptom Two or more sleep difficulty symptoms
ollowing: Reporting two or more of the following:
eep • Difficulty falling asleep
sleep • Difficulty staying asleep
• Waking too early
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as “fibromyalgia” to respondents) was included in this
list. All respondents who selected FM were subsequently
asked “has your fibromyalgia been diagnosed by a phys-
ician?”, with yes/no response options. Only respondents
who reported a diagnosis of FM were considered to have
FM for the purposes of this study and the remaining
respondents were considered controls.
Demographic and health history variables
Age, race/ethnicity (non-Hispanic white, non-Hispanic
black, Hispanic, or other race/ethnicity), marital status
(married/living with partner versus all else), education
(high school graduate or less versus some college or
higher), annual household income ($25K or less, $25K
to <$50K, $50K to <$75K, $75K or more, or decline to
answer), employment (full-time, part-time, self-employed,
not employed and not looking for work, not employed but
looking for work, on disability, retired, student, or home-
maker), health insurance (yes versus no), exercise (no days
with 20 minutes or more of exercise in the past month,
1–9 days, or 10 or more days), smoking habits (current
smoker versus non-smoker), alcohol consumption (con-
sume alcohol versus abstain from alcohol), body mass
index (BMI; underweight, normal weight, overweight,
obese, or decline to provide weight), and comorbidity
burden (using the Charlson Comorbidity Index; CCI
[20]) were assessed.
Pain severity (no pain, mild pain, moderate pain, and
severe pain) and frequency (no pain, daily pain, 4–6 days
of pain per week, 2–3 days of pain per week, weekly
pain, 2–3 days of pain per month, 1 day of pain a month
or less) information were also measured for each
respondent.
Health-related quality of life
HRQoL was assessed using the the Medical Outcomes
Study Short Form-12 questionnaire (SF-12), version 2,
which has a four-week recall period [21]. The SF-12 was
developed to replicate the mental (MCS) and physical
component summary (PCS) scores and domain scores of
the SF-36. The eight health domains include: physical
functioning, physical role limitations, emotional role lim-
itations, bodily pain, general health, vitality, social func-
tioning, and mental health. The PCS and MCS are
normed to the US population (Mean = 50, SD = 10), with
higher scores indicating greater quality of life. Differences
of 3 points in MCS and PCS were considered clinically
meaningful, in accordance with previous findings [22].
Analyses
There were four components to the analysis. In the first,
the prevalence of sleep difficulty symptoms among
patients with FM were reported and compared withthose without FM (both unmatched and matched con-
trols) using chi-square tests. Unmatched controls were
defined as those who did not report a diagnosis of FM.
Matched controls were created using a propensity score
matching method [23].
A logistic model was conducted using age, gender,
race/ethnicity, and comorbidities (using the CCI) to pre-
dict a diagnosis of FM. Propensity score values were
saved from this regression and used in a greedy-
matching algorithm to assign each patient diagnosed
with FM with a single control, whose propensity score
was identical. Although there were 2,196 patients diag-
nosed with FM, only 2,194 patients were able to be
matched (the remaining two patients had a pattern of
covariates which was too unique to find a suitable con-
trol). Therefore, there were 2,194 matched controls.
The second component of the analysis compared the
different symptom groups (no sleep difficulty symptoms
versus one sleep difficulty symptom versus two or more
sleep difficulty symptoms) among those with FM with
respect to demographics and health history variables
noted above. Comparisons were made with chi-square
tests and one-way ANOVAs.
The third component of the analysis consisted of regres-
sing summary and domain scores of the SF-12 onto the
number of sleep difficulty symptoms (none, one, or two or
more) among patients with FM. These models were con-
ducted using linear regression for complex survey designs
(PROC SURVEYREG in SAS v9.1). For the sake of parsi-
mony, only covariates which differed among the groups
were included in the model: age, smoking status (non-
smoker served as the reference category), pain severity (no
pain served as the reference category), and pain frequency
(no pain served as the reference category).
The fourth component of the analysis was a compari-
son of the relationship of sleep difficulty symptoms and
HRQoL between those with FM and matched controls.
This was accomplished by entering the case variable
(diagnosed FM versus matched control), number of sleep
symptoms (none, one, and two or more), and the inter-
action term into a linear regression model (PROC
SURVEYREG) for each summary and domain score.
Effects coding was used for all variables. This model
tested the main effect (i.e., whether HRQoL was different
between those with FM and matched controls) as well as
the interaction (i.e., whether the relationship between
the number of sleep symptoms and HRQoL differed be-
tween patients with FM and matched controls).
All analyses applied sampling weights from the NHWS.
Although raw sample sizes are provided in many cases, all
other statistical information (unless otherwise specified)
were weighted to project to the population. Analyses were
conducted using SAS v9.1 (Cary, NC) and statistical sig-
nificance was set at p<.05.
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Frequency of sleep difficulty symptoms
A total of 2,196 patients in the NHWS reported diagno-
sis of FM (2.81%). Of these, 269 (11.2%) reported no
sleep difficulty symptoms, 574 (25.7%) reported one
sleep difficulty symptom, and 1353 (63.05%) reported
two or more sleep difficulty symptoms. The prevalence
of sleep difficulty symptoms was significantly higher
when compared with those without FM (none: 40.7%;
one: 29.0%; two or more: 30.3%; p<.0001). Indeed, even
when comparing patients with FM with matched con-
trols (those matched on age, sex, ethnicity, and comor-
bidities), the prevalence of sleep difficulty symptoms was
significantly higher (none: 11.2% vs. 32.9% for FM and
matched control patients, respectively; one: 25.7% vs.
28.22%, respectively; two or more: 63.1% vs. 38.9%, re-
spectively; p<.0001).
Demographic and health history comparisons
Among patients with FM, few demographic and health
history variables were related to the number of sleep
symptoms experienced (see Table 2). Patients with FM
who reported sleep difficulties were younger, less likely
to be retired and possess health insurance, and more
likely to be on disability and to currently smoke. Levels
of severe pain increased concomitantly with the number
of sleep symptoms (19.08% vs. 30.77% vs. 43.26% for
those with none, one, and two sleep difficulty symptoms,
respectively). Similarly, reports of daily pain also
increased along with the number of sleep difficulty
symptoms (49.21% vs. 59.67% vs. 70.88%).
Association of sleep difficulty symptoms and health-
related quality of life
The distributions of all HRQoL summary and domain
scores for those with FM are presented in Table 3. Linear
regressions were conducted to determine the relationship
between the number of sleep difficulty symptoms and
HRQoL among those with FM (see Table 4). For all sum-
mary and domain scores, the experience of sleep difficulty
symptoms was associated with a significant decrement
relative to those without any sleep difficulty symptoms. In
the case of the normed mental and physical component
summary scores, the effects of both one (b’s: -2.79 and
−2.42, respectively) and two sleep difficulty symptoms (b’s:
-3.91 and −2.84, respectively) approached or exceeded
clinically-relevant thresholds (i.e., 3 points).
Similarly, decrements in health utility values (b =
−0.04 and −0.05 for one and two sleep difficulty symp-
toms, respectively) were also above clinically-relevant
thresholds (i.e., 0.03 points). The SF-12 domain scores
for those with one sleep difficulty symptom were equally
affected (generally speaking) compared with those with
no sleep difficulty symptoms (b’s ranged from −4.37 to−9.49); similarly, the SF-12 domain scores for those with
two sleep difficulty symptoms were also equally affected
compared with those with no sleep difficulty symptoms
(b’s ranged from −6.64 to −10.84).
Additional models were then conducted to determine
whether the relationship between sleep difficulty symp-
toms and HRQoL was different among those with FM
than a similar cohort without FM. When compared with
matched controls, patients with FM reported significantly
worse HRQoL across all summary and domain scores of
the SF-12 (i.e., “main effects”; see Table 5; all p<.0001).
However, the relationships between the number of
sleep difficulty symptoms and HRQoL was significantly
stronger among those with FM. In other words, signifi-
cant interactions were observed for all summary and do-
main scores (with the exception of emotional role
limitations). In most cases, the decrement between no
sleep difficulty symptoms and one sleep difficulty symp-
tom was larger among those patients with FM; con-
versely, the quality of life decrement between one and
two or more sleep difficulty symptoms was larger among
matched controls.
Discussion
The objective of the current study was to assess the im-
pact of sleep difficulties on HRQoL among patients with
FM. Despite the research on the sleep-related symptoms
experienced by those with FM, no study to our knowledge
has examined the relationship of these symptoms with
HRQoL, especially in comparison with a matched control
group. Our results suggest sleep difficulties are pervasive
among the FM population, as over 88% of patients
reported some level of sleep difficulties, as defined by ex-
periencing either difficulty falling asleep, difficulty staying
asleep, or waking up too early. Nearly 63% of patients with
FM reported experiencing at least two of the above symp-
toms. These figures were significantly higher than those
without FM, even those matched with FM patients.
Replicating past literature, our sample of patients with
FM reported significant decrements in both MCS
(41.49) and PCS (31.29) scores relative to population
norms (50 and 50, respectively). Indeed, the one and
two standard deviation differences, respectively, in MCS
and PCS compared with the population mean is nearly
identical to the results reported by previous literature
[6,7]. On an absolute level, these levels of HRQoL are
worse than reported in the same survey for patients
with severe osteoarthritis, chronic obstructive pulmon-
ary disease, atrial fibrillation, hepatitis C, arthritis, and
back pain, among others [24-28], However, our findings
suggest that the presence of sleep difficulties poses an
additional burden on patients with FM. Our results
suggest that sleep difficulty symptoms has an independ-
ent, and significant, clinically-meaningful effect on



























231 579865 82.11% 2.72% 480 1297016 80.03% 1.93% 1096 3060560 77.12% 1.34%
Non-Hispanic
black
16 44654 6.32% 1.55% 36 95814 5.91% 0.97% 80 207978 5.24% 0.58%
Hispanic 12 51952 7.36% 2.08% 34 160905 9.93% 1.63% 82 396647 9.99% 1.06%
Other 10 29762 4.21% 1.34% 24 66882 4.13% 0.86% 95 303503 7.65% 0.86%
Greater than high
school education
205 548338 77.64% 2.86% 445 1254870 77.43% 1.89% 1041 3115084 78.49% 1.17% 0.8776
Annual household income 0.0906
<$25K 67 164262 23.26% 2.91% 157 453920 28.01% 2.06% 405 1194941 30.11% 1.35%
$25K to <$50K 75 209604 29.68% 3.2% 162 450214 27.78% 2.04% 431 1254027 31.60% 1.37%
$50K to <$75K 59 161650 22.89% 2.87% 125 329591 20.34% 1.75% 234 691354 17.42% 1.08%
$75K or more 47 128776 18.23% 2.65% 100 294962 18.20% 1.74% 228 687512 17.32% 1.1%
Decline to
answer
21 41942 5.94% 1.4% 30 91929 5.67% 1.09% 55 140853 3.55% 0.51%
Employment <.0001
Full-time 40 129881 18.39% 2.69% 96 302795 18.68% 1.78% 204 637364 16.06% 1.06%
Part-time 21 56486 8.00% 1.76% 58 161415 9.96% 1.31% 132 379165 9.55% 0.83%
Self-employed 17 46951 6.65% 1.62% 30 85771 5.29% 0.99% 81 248640 6.27% 0.69%
Unemployed,
looking for work
12 32426 4.59% 1.35% 22 59646 3.68% 0.8% 75 231083 5.82% 0.68%
Unemployed,
not looking
2 4421 0.63% 0.48% 15 43845 2.71% 0.7% 63 186145 4.69% 0.59%
Retired 114 258239 36.57% 3.39% 160 391288 24.14% 2.02% 283 715123 18.02% 1.22%
Disability 40 116650 16.52% 2.46% 133 394200 24.32% 1.89% 379 1154974 29.10% 1.31%
Student 1 2271 0.32% 0.32% 6 21302 1.31% 0.56% 15 47148 1.19% 0.31%
Homemaker 22 58909 8.34% 1.81% 54 160354 9.89% 1.34% 121 369046 9.30% 0.83%
Married/living with
partner
162 420899 59.60% 3.41% 353 968068 59.73% 2.26% 816 2426243 61.13% 1.43% 0.8299
Possess health
insurance












92 241295 34.17% 3.25% 152 455112 28.08% 2.06% 373 1076395 27.12% 1.28%
Alcohol use 140 367023 51.97% 3.44% 299 835869 51.58% 2.27% 672 1991970 50.19% 1.46% 0.8168
Current smoker 58 163896 23.21% 2.95% 171 515809 31.83% 2.11% 405 1227589 30.93% 1.34% 0.0405
Body mass index 0.1211
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Table 3 Descriptive statistics of summary and domain scores of the SF-12 among patients with fibromyalgia
Min % at Min Q1 Median Mean Q3 Max % at Max
Summary scores
Mental component summary 3.57 0.05% 31.98 41.07 41.49 51.22 71.53 0.05%
Physical component summary 7.25 0.05% 23.99 31.29 31.29 39.88 63.16 0.05%
Health utilities 0.35 1.50% 0.49 0.57 0.57 0.64 1.00 0.23%
Domain scores
Bodily pain* 0.00 20.49% 25.00 25.00 25.00 50.00 100.00 2.41%
General health* 0.00 13.34% 25.00 25.00 25.00 60.00 100.00 1.55%
Vitality* 0.00 30.78% 0.00 25.00 25.00 50.00 100.00 1.14%
Social functioning* 0.00 12.66% 25.00 50.00 50.00 75.00 100.00 13.93%
Mental health** 0.00 2.73% 37.50 50.00 50.00 75.00 100.00 1.82%
Emotional role limitations** 0.00 8.24% 37.50 50.00 50.00 87.50 100.00 21.36%
Physical role limitations** 0.00 21.04% 12.50 25.00 25.00 50.00 100.00 4.74%
Physical functioning* 0.00 29.96% 0.00 25.00 25.00 50.00 100.00 10.75%
*Note these domains scores from the SF-12 are based only on a five-point range (0, 25, 50, 75, 100).
**Note these domains scores from the SF-12 are based only on a 9-point range (0, 12.5, 25, 37.5, 50, 62.5, 75, 87.5, 100).
Table 2 Demographic and health history differences associated with the number of sleep difficulty symptoms among
patients with fibromyalgia (Continued)
Underweight 5 9180 1.30% 0.67% 11 35633 2.20% 0.68% 16 42536 1.07% 0.28%
Normal 53 144538 20.47% 2.87% 128 397673 24.54% 2.01% 277 811375 20.44% 1.17%
Overweight 80 208488 29.52% 3.13% 168 462626 28.55% 2.04% 346 1061443 26.75% 1.34%
Obese 120 309173 43.78% 3.39% 257 696615 42.98% 2.23% 682 1956748 49.30% 1.46%
Decline to
answer weight
11 34856 4.94% 1.6% 10 28070 1.73% 0.55% 32 96584 2.43% 0.44%
Pain severity <.0001
No pain 79 217295 30.77% 3.16% 129 373430 23.04% 1.94% 217 611959 15.42% 1.03%
Mild pain 10 32456 4.60% 1.7% 34 87366 5.39% 0.97% 29 83328 2.10% 0.41%
Moderate pain 113 295400 41.83% 3.42% 217 593646 36.63% 2.16% 514 1503698 37.89% 1.42%
Severe pain 57 134783 19.08% 2.5% 175 498641 30.77% 2.08% 574 1716877 43.26% 1.46%
Missing severity 10 26300 3.72% 1.23% 19 67533 4.17% 1% 19 52824 1.33% 0.31%
Pain frequency <.0001
No pain 79 217295 30.77% 3.16% 129 373430 23.04% 1.94% 217 611959 15.42% 1.03%
Daily pain 140 347542 49.21% 3.43% 347 966989 59.67% 2.23% 955 2813110 70.88% 1.31%
4-6 days per
week
18 44232 6.26% 1.55% 40 107597 6.64% 1.07% 105 320622 8.08% 0.8%
2-3 days per
week
11 37374 5.29% 1.9% 28 74165 4.58% 0.91% 43 128377 3.23% 0.51%
Weekly pain 2 6227 0.88% 0.64% 6 19050 1.18% 0.48% 7 19631 0.49% 0.19%
2-3 days per
month or less
9 27264 3.86% 1.45% 5 11852 0.73% 0.35% 7 22164 0.56% 0.21%








Age 57.56 56.04 1.07 53.36 51.90 0.7 52.47 51.63 0.39 0.0006
Charlson comorbidity
index
1.1 1.11 0.11 1.3 1.34 0.13 1.18 1.17 0.05 0.3475
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Table 4 Regression estimates for the number of sleep difficulty symptoms when predicting health-related quality of
life
Dependent variable No symptoms (reference) One symptom Two or more symptoms
Mental component summary b – −2.786 −3.905
95% CL – (−4.448, -1.124) (−5.461, -2.35)
R2 0.174
Physical component summary b – −2.415 −2.835
95% CL – (−4.144, -0.686) (−4.467, -1.202)
R2 0.241
Health utilities b – −0.041 −0.054
95% CL – (−0.06, -0.022) (−0.072, -0.035)
R2 0.284
Bodily pain b – −5.770 −8.555
95% CL – (−9.729, -1.811) (−12.239, -4.87)
R2 0.312
General health b – −6.349 −8.441
95% CL – (−10.358, -2.34) (−12.222, -4.66)
Vitality R2 0.153
b – −5.943 −6.637
95% CL – (−9.994, -1.893) (−10.447, -2.827)
R2 0.097
Social functioning b – −7.327 −10.838
95% CL – (−11.741, -2.913) (−14.906, -6.771)
R2 0.205
Mental health b – −4.366 −8.658
95% CL – (−7.71, -1.021) (−11.805, -5.511)
R2 0.184
Emotional role limitations b – −8.094 −7.546
95% CL – (−12.802, -3.387) (−11.847, -3.245)
R2 0.120
Physical role limitations b – −9.485 −10.416
95% CL – (−14.043, -4.928) (−14.683, -6.148)
R2 0.194
Physical functioning b – −6.015 −6.915
95% CL – (−11.315, -0.715) (−11.867, -1.963)
R2 0.177
Regression coefficients represent the difference in HRQoL for those with one and two symptoms relative to those without any (e.g., those with one symptom and two or
more symptoms reported mental component summary scores 2.786 and 3.905 points less, respectively, than those without symptoms). All models controlled for age,
smoking status, pain severity, and pain frequency.
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suggested a three-point between-groups difference in
MCS and PCS is often associated with a clinically-
meaningful difference [21]. The comparison between
one sleep difficulty symptom and no sleep difficulty
symptoms approached this threshold while the com-
parison between two sleep difficulty symptoms and no
sleep difficulty symptoms exceeded it, even after adjust-
ing for confounding variables.It is particularly important to note that these models
controlled for pain severity and frequency. Naturally, se-
vere pain and frequent pain (as confirmed in Table 2)
would be expected to have a significant effect on sleep
symptoms, as also demonstrated in prior research
[14,16,20,22]. Yet, even accounting for the higher preva-
lence of pain severity and frequency among those with
more sleep difficulty symptoms, worse HRQoL summary
and domain scores were observed. This suggests that
Table 5 Mean levels of health-related quality of life for patients with fibromyalgia and matched controls as a function
of sleep difficulty symptoms






























46.56 43.51 41.68 35.91 33.24 31.57 <.0001 0.0445
Health utilities 0.77 0.71 0.66 0.64 0.59 0.55 <.0001 <.0001
Bodily pain 75.45 66.86 59.69 46.00 37.94 31.04 <.0001 0.0028
General health 67.34 59.82 54.99 52.86 43.75 39.49 <.0001 0.0097
Vitality 53.66 46.74 37.57 36.52 28.54 25.67 <.0001 <.0001
Social
functioning
83.05 73.86 63.59 63.66 52.01 44.92 <.0001 0.0003
Mental health 74.01 64.94 56.79 64.73 55.75 49.06 <.0001 <.0001
Emotional role
limitations
83.26 76.47 69.59 69.80 58.26 55.14 <.0001 0.0545
Physical role
limitations
73.34 63.38 56.45 48.19 36.39 31.88 <.0001 0.0069
Physical
functioning
74.23 64.98 58.95 46.47 39.51 34.59 <.0001 0.0151
The p-value for the main effect represents the significance of the HRQoL differences between patients with FM and matched controls across all levels of symptoms. The
p-value for the interaction represents the significance of whether the change from no symptoms to one symptom to two or more symptoms was different between
patients with FM and matched controls.
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among those with FM, beyond any potential effect of the
pain experience.
Also noteworthy was that the relationship between
sleep difficulties and HRQoL varied between those with
FM and matched controls. In many cases, the introduc-
tion of a single sleep difficulty symptom was associated
with a larger decrement in HRQoL among patients with
FM, however, the introduction in a second sleep diffi-
culty symptom was associated with larger decrement in
HRQoL among matched controls. Further research may
be necessary to ascertain the cause of the discrepancy.
One possibility is that sleep difficulties are generally
more burdensome for patients with FM, however, given
the nature of the disease, a floor effect is reached upon
the introduction of the second sleep difficulty symptom.
In other words, patients with FM are so burdened
already by their condition that the introduction of an
additional sleep difficulty symptom does not affect their
HRQoL as much as it would a patient without FM. Re-
gardless, our preliminary evidence suggests that the pat-
tern of the relationship between sleep difficulty
symptoms and HRQoL is unique among those with FM.
The effect of sleep difficulty symptoms extended be-
yond HRQoL. In unadjusted comparisons, patients who
reported sleep difficulties showed higher rates ofdisability than those without sleep difficulties. Although
beyond the scope of the present analysis, the effect of
sleep difficulties on participation in the labor force and
productivity at work may also need to be considered in
future research.
In sum, the results suggest patients with FM experience
considerable difficulty initiating and maintaining sleep.
The presence of these sleep difficulty symptoms have a
significant and clinically-meaningful impact on HRQoL,
even after accounting for a range of confounding vari-
ables. The study results suggest the improved manage-
ment of these sleep difficulty symptoms among patients
with FM may lead to clinically-relevant improvements in
HRQoL. The alleviation of pain could have an important
effect of improving sleep, but more research would be
necessary to establish this causal pathway. Indeed, the re-
lationship between pain and sleep does appear bidirec-
tional [29]. Of course, since the effect of sleep difficulty
symptoms on HRQoL was observed even after control-
ling for pain, the management of sleep difficulties likely
extends beyond the mere alleviation of pain.
Limitations
Several limitations should be noted from the results of this
study. Given the cross-sectional design of the study, the
causal inference cannot be determined. Although alternative
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demographic confounders), it is possible other unmeasured
variables might explain the relationship between sleep diffi-
culties and HRQoL. Because of the self-reported nature, re-
call bias may have introduced additional error into the
observed associations. As described before, the sleep diffi-
culty groups were not defined by a sleep scale but rather
using three symptoms of initiating and maintaining sleep to
operationalize sleep difficulty severity. It should also be
emphasized that although the NHWS is demographically
representative of the US population, the sample in the
current study of FM patients may differ with respect to
healthcare attitudes or healthcare engagement (among other
variables) that could affect the size and direction of the rela-
tionships observed here.
Conclusions
Sleep difficulties were found to have significant and clin-
ically meaningful deleterious effects on HRQoL among
the FM population. Effective treatment of sleep difficul-
ties may improve HRQoL among the FM population.
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